SCHEMBL981640

SCHEMBL981640

N#Cc1cccc(C2=NN(C(=O)Cc3ccc(F)cc3)CC2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.43
PRKAA2 P54646 1/20 0.42
KIT P10721 1/20 0.42
KCNK3 O14649 3/20 0.40
VNN1 O95497 1/20 0.40
PTGER1 P34995 1/20 0.40
CCR3 P51677 4/20 0.39
HTR2A P28223 2/20 0.39
MAPK1 P28482 1/20 0.39
SCN9A Q15858 1/20 0.39
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
CCR5 P51681 1/20 0.38
NPY5R Q15761 1/20 0.38
GRM5 P41594 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL979341 0.90 LMNA (0.44) CCR3GABRG2GABRB3GABRA5GABRA3
SCHEMBL982313 0.87 MAOB (0.45) PTGDR2ALDH1A1
SCHEMBL982843 0.87 SMN1; SMN2 (0.54) VNN1ALDH1A1
SCHEMBL1427068 0.84 ORAI1 (0.42) ALDH1A1
SCHEMBL984691 0.82 MAOB (0.49) MAPK1USP2ALDH1A1CYP2C9TSHR
SCHEMBL980870 0.81 MAOB (0.53) KCNK3USP2ALDH1A1
SCHEMBL980144 0.81 MAOB (0.55) ALDH1A1CYP2C9TSHR
SCHEMBL983003 0.80 MAPT (0.52) NPY5RALDH1A1
SCHEMBL1427074 0.79 MET (0.41)
SCHEMBL14484302 0.78 CYP3A4 (0.47) MAPK1GRM5USP2ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 PTGDR2 1164/4885PRKAA2 226/4885KIT 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.